There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eledon Pharmaceuticals (ELDN – Research Report) and Stereotaxis (STXS – Research Report) with bullish sentiments.
Eledon Pharmaceuticals (ELDN)
LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Eledon Pharmaceuticals today and set a price target of $9.00. The company’s shares closed last Thursday at $1.23, close to its 52-week low of $1.20.
According to TipRanks.com, Katkhuda is a 4-star analyst with an average return of
Eledon Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $17.00.
See Insiders’ Hot Stocks on TipRanks >>
Stereotaxis (STXS)
In a report released today, Neil Chatterji from B.Riley Financial maintained a Buy rating on Stereotaxis, with a price target of $4.50. The company’s shares closed last Thursday at $1.61.
According to TipRanks.com, Chatterji is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Stereotaxis with a $4.50 average price target, representing a 206.1% upside. In a report released yesterday, Craig-Hallum also assigned a Buy rating to the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ELDN:
